Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Erik S. Mittra; Harshad R. Kulkarni; Christophe M. Deroose; Rajaventhan Srirajaskanthan; John Ramage; Chiara Maria Grana; Francesca Botta; Matthias M. Weber; Matthias Miederer; Ryan Reddy; Daniela Chicco; Maurizio F. Mariani; Arnaud Demange; Jack L. Erion; Germo Gericke; Eric Krenning

doi:10.2967/jnumed.124.268903

Research ArticleClinical Investigation

Open Access

Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Lisa Bodei, Marta Cremonesi, Mahila Ferrari, Erik S. Mittra, Harshad R. Kulkarni, Christophe M. Deroose, Rajaventhan Srirajaskanthan, John Ramage, Chiara Maria Grana, Francesca Botta, Matthias M. Weber, Matthias Miederer, Ryan Reddy, Daniela Chicco, Maurizio F. Mariani, Arnaud Demange, Jack L. Erion, Germo Gericke and Eric Krenning

Journal of Nuclear Medicine March 2025, 66 (3) 449-456; DOI: https://doi.org/10.2967/jnumed.124.268903

Lisa Bodei

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marta Cremonesi

2Radiation Research Unit, Istituto Europeo di Oncologia, IRCCS, Milan, Italy;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mahila Ferrari

3Medical Physics Unit, Istituto Europeo di Oncologia, IRCCS, Milan, Italy;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erik S. Mittra

4Division of Molecular Imaging and Therapy, Oregon Health and Science University, Portland, Oregon;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Harshad R. Kulkarni

5Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christophe M. Deroose

6Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Rajaventhan Srirajaskanthan

7Neuroendocrine Tumour Unit, ENETS Centre of Excellence, King’s College Hospital, London, United Kingdom;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John Ramage

8Department of Gastroenterology and Hepatology, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chiara Maria Grana

9Division of Nuclear Medicine, Istituto Europeo di Oncologia, IRCCS, Milan, Italy;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francesca Botta

3Medical Physics Unit, Istituto Europeo di Oncologia, IRCCS, Milan, Italy;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias M. Weber

10Department of Endocrinology and Metabolism, I Medical Clinic, Johannes Gutenberg University of Mainz, Mainz, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias Miederer

11Clinic of Nuclear Medicine, Johannes Gutenberg University of Mainz, Mainz, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ryan Reddy

1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daniela Chicco

12Advanced Accelerator Applications, a Novartis company, Via Ribes, Italy;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maurizio F. Mariani

12Advanced Accelerator Applications, a Novartis company, Via Ribes, Italy;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Arnaud Demange

13Advanced Accelerator Applications, a Novartis company, Geneva, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jack L. Erion

14Advanced Accelerator Applications, a Novartis company, New York, New York; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Germo Gericke

13Advanced Accelerator Applications, a Novartis company, Geneva, Switzerland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eric Krenning

15Cyclotron Rotterdam BV, Erasmus Medical Center, Rotterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 3

March 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Journal of Nuclear Medicine Mar 2025, 66 (3) 449-456; DOI: 10.2967/jnumed.124.268903

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Journal of Nuclear Medicine Mar 2025, 66 (3) 449-456; DOI: 10.2967/jnumed.124.268903

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

[177Lu]Lu-DOTATATE
dosimetry
neuroendocrine tumors
peptide receptor radionuclide therapy
radiopharmaceutical therapy

Main menu

User menu

Search

Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords